Home > Boards > Free Zone > Health and Sciences > Biotech Values

OXGN trading under cash value with two Phase

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jaybird249 Member Profile
 
Followed By 80
Posts 2,931
Boards Moderated 0
Alias Born 05/05/06
160x600 placeholder
Top Company News of the Day
The company said some products showed traces of benzene, a cancer-causing chemical, and that customers should throw the sprays away.
Moderna to Test Variant-Specific Vaccine Candidate
Corn Rises as Agriculture Assets Dodge Broader-Market Sell-Off -- Daily Grain Highlights
Marriott, Hilton and Other Lodging Stocks Down as Variant Concerns Prompt Broad Decline
Uber Down 4%, Lyft Declines 5%
Unemployment Rate Seen Ticking Down Again -- Data Week Ahead
Front Month Nymex RBOB Gasoline Fell 8.25% This Week to Settle at $2.0294 -- Data Talk
Front Month Nymex Natural Gas Rose 7.54% This Week to Settle at $5.4470 -- Data Talk
Correction to European Indexes Data Talks on Nov. 24
STOXX Europe 50 Index Ends the Week 4.41% Lower at 3606.58 -- Data Talk
EURO STOXX 50 Index Ends the Week 6.13% Lower at 4089.58 -- Data Talk
DAX Ends the Week 5.59% Lower at 15257.04 -- Data Talk
CAC 40 Index Ends the Week 5.24% Lower at 6739.73 -- Data Talk
STOXX Europe 600 Index Ends the Week 4.53% Lower at 464.05 -- Data Talk
FTSE 100 Index Ends the Week 2.49% Lower at 7044.03 -- Data Talk
Telenor Appeal to Overturn $87.8 Million Fine Is Rejected by Norwegian Court
Sartorius to Invest EUR100 Million in France by 2025, Create Up to 400 Jobs
FTSE 100 Closes Friday Down as Latest Coronavirus Variant Sparks Sell-off
Theme Park Stocks Fall Amid Coronavirus Variant Concerns
Covid-19 Vaccine Maker Stocks Higher Amid Variant Concerns
Boeing Down Nearly 8%, On Track for Largest Percent Decrease Since June 2020 -- Data Talk
BioNTech Up Nearly 21%, On Pace for Largest Percent Increase Since May 2020 -- Data Talk
American Express Down Over 8%, Worst Performer in the DJIA So Far Today -- Data Talk
jaybird249   Wednesday, 09/30/15 06:12:22 AM
Re: DewDiligence post# 195457
Post # of 240489 
OXGN trading under cash value with two Phase 2/3 studies. Another catalyst in a few weeks:

Phase 1b/2 pazopanib/fosbretabulin combo trial: Results from the dose-range portion of this trial being led by The Christie NHS Foundation Trust will be presented at the European Society of Gynaecological Oncology taking place October 24-27. Why is this trial exciting? The belief is that is this could be a very effective combo treatment given that fosbretabulin effectively targets the cancer blood vessels that are newly forming near the center of the cancer while pazopanib targets the more established blood vessels that fosbretabulin doesn't address

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences